Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2017-05-12 Capital/Financing Update
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Communications during bidding periods / Other releases
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the successful completion of a capital increase, detailing the number of shares issued, the price, the total funds raised (€4 million), and the intended use of the funds. This activity directly relates to the company's financing and capital structure. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it describes a specific corporate finance action.
2017-05-12 English
Communiqués en période d’offre / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document explicitly announces the success of a capital increase ('augmentation de capital') amounting to 4 M€, detailing the number of new shares issued, the price, and the resulting percentage of the share capital. This action directly relates to changes in the company's financing and capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV).
2017-05-12 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 99% confidence The document is titled "Theradiag announces the launch of a capital increase" and details the issuance of new shares, the maximum amount (€4 million), the use of an accelerated bookbuilding process, and references authorization from the General Meeting of Shareholders. This clearly describes a corporate financing activity involving the issuance of new equity. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the AGM resolution authorizing the action, the primary subject is the capital increase itself, not the AGM materials or voting results.
2017-05-11 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is titled "Theradiag annonce le lancement d'une augmentation de capital" (Theradiag announces the launch of a capital increase). The text explicitly details the launch of a capital increase by issuing new shares without preferential subscription rights, authorized by the General Meeting and the Board. This action directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it mentions the 2016 Annual Report for risk factors, the primary purpose and content of this specific announcement is the capital operation.
2017-05-11 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French commercial code and AMF (Autorité des Marchés Financiers) regulations, and presents a table detailing the total number of shares and theoretical voting rights as of April 30, 2017. This type of mandatory disclosure regarding the capital structure and voting rights is a specific corporate action announcement. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS). It most closely aligns with announcements related to capital structure changes or share information, which points towards 'Share Issue/Capital Change' (SHA) or potentially a specific regulatory filing. Given the precise nature of reporting total shares and voting rights, it fits best under the category related to capital structure changes, which is SHA. However, since it is a mandatory disclosure of the current share count and voting rights, it is a very specific type of regulatory update. Reviewing the definitions, SHA covers 'new share issues, stock splits, or other capital changes.' While this is a periodic update on the *existing* capital structure, it is a direct consequence of capital movements. Alternatively, it could be seen as a general regulatory filing (RNS). Since the document is short and is a direct publication of required data rather than an announcement *about* a report, I will check the most relevant specific category. The closest fit among the specific codes is SHA, as it relates directly to the share count. If SHA is too broad, RNS is the fallback. Given the content is purely about the share count and voting rights, SHA is the most precise fit among the provided options for capital structure reporting.
2017-05-04 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references the French Commercial Code and AMF (Autorité des Marchés Financiers) regulations. The core content is a table showing the total number of shares and voting rights as of a specific date (March 31, 2017). This type of mandatory disclosure regarding the total share capital and voting rights is a specific corporate action announcement, not a comprehensive annual report (10-K), interim report (IR), or a general regulatory filing (RNS). It most closely aligns with announcements related to capital structure changes or share counts, which fits best under 'Share Issue/Capital Change' (SHA) or potentially a specific regulatory filing. Given the options, 'SHA' (Share Issue/Capital Change) covers changes or updates to the capital structure, which includes the total number of shares outstanding. However, since this is a routine disclosure of the total share count, and not an issuance or repurchase itself, it is a specific regulatory disclosure. Reviewing the definitions, 'SHA' is for 'Announcement regarding new share issues, stock splits, or other capital changes.' While this is a change in the *count* due to expiration of a specific voting right mechanism, it is fundamentally about the capital structure. Alternatively, 'RNS' (Regulatory Filings) is a fallback. Given the highly specific nature of the disclosure (total shares/voting rights), and the lack of a perfect fit, I will check if 'SHA' is the best fit. Since it is a notification about the current state of the capital structure, 'SHA' is plausible. However, if we consider the nature of the filing (a mandatory disclosure of share count under AMF rules), it is a very specific type of regulatory update. Let's re-evaluate the options. It is not a dividend (DIV), director dealing (DIRS), or earnings release (ER). It is a formal notification about the capital base. 'SHA' seems the most appropriate category for updates concerning the total number of shares outstanding, even if it's a periodic update rather than a transaction. I will classify it as SHA.
2017-04-04 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.